UAE approves Foundayo obesity pill offering needle-free weight loss / Image: File

In a major health care shift, the United Arab Emirates has approved Foundayo (orfoglypron), a daily oral obesity pill developed by Eli Lilly. The decision by Emirates Drug Establishment places the country among the first countries in the world to introduce needle-free alternatives to injectable weight loss treatments.The approval comes as obesity is increasingly linked to serious long-term conditions, including type 2 diabetes, heart disease and some cancers. The convenience of Foundaio is what makes it different. Unlike injectable GLP-1 medications, it is taken as a simple daily pill and does not require a strict schedule for food or water intake, making it easier for patients to adhere to.

UAE offers needle-free obesity pill weight loss

Despite the growing buzz, Foundation is not for casual or cosmetic use. It will be available only through prescription and under strict medical supervision. Doctors in the UAE are expected to follow clear eligibility guidelines before prescribing a medicine.Patients are typically eligible if they have a body mass index (BMI) of 30 or higher, which falls under clinical obesity, or a BMI above 27 with associated health conditions. These include metabolic and lifestyle diseases like diabetes, high blood pressure, high cholesterol, sleep apnea and joint stress conditions.Before starting treatment, patients must undergo a detailed medical evaluation. These include blood tests, metabolic checks, and a thorough review of the medical history. Specialists such as endocrinologists and internal medicine specialists will play a central role in determining whether a medication is appropriate, ensuring that its use is targeted and medically appropriate.

How does Foundayo Weight Loss Pill work?

Foundaio belongs to a class of drugs called GLP-1 receptor agonists, which mimic natural hormones in the body that regulate appetite and blood sugar levels. Practically, the drug helps patients feel full earlier, reduce hunger signals, and reduce overall calorie intake without drastic dietary restrictions.Clinical trials have shown strong and consistent results. Patients taking the higher doses experienced an average weight loss of 12.4 percent, with some studies reporting a loss of nearly 12 kilograms over a 72-week period. In addition to weight loss, early findings also suggest improvements in cholesterol levels, blood pressure and markers associated with heart disease risk, pointing to broader metabolic benefits.Also, doctors warn that side effects are possible, especially during the early stages of treatment. Some patients reported nausea, mild digestive discomfort, and gastrointestinal problems, especially when dosage levels were increased. These effects were generally manageable but highlight the importance of medical supervision during the treatment process.

When will it be available in UAE?

The pill is expected to be available in UAE pharmacies from May 2026, but access will be controlled through prescription channels. Health experts are clear that Foundaio is not a shortcut or a one-time solution. Instead, it is designed as part of a long-term treatment plan.In many cases, patients may need to remain on medication for a long time, sometimes lifelong, depending on their condition. Doctors emphasize that stopping the medication without lifestyle changes such as a balanced diet and regular exercise can lead to weight gain again. Medications work best when combined with sustained behavioral changes rather than replacing them.There are also explicit medical exclusions. The medication is not recommended for women who are pregnant or breastfeeding, and it may not be suitable for individuals with certain thyroid cancers, endocrine disorders, or severe gastrointestinal and kidney conditions. These restrictions reinforce the need for careful investigation before starting treatment.

Expected price of Foundaio in UAE

Although the official price of Foundaio in the UAE has not yet been confirmed, early estimates suggest it could be placed within the same range as existing GLP-1 treatments. The injectable options currently available in the UAE often cost between Dh800 and Dh1,500 per month, depending on the dose and brand.Industry experts expect Foundaio to be priced competitively within this bracket, although its oral format could impact final pricing depending on demand and insurance coverage. Another important factor will be whether UAE insurers classify the drug under essential obesity treatment or alternative medicine, which could significantly impact patients’ out-of-pocket costs.Affordability is likely to play an important role in adoption. While the convenience of a daily pill is expected to attract strong demand, long-term use means that pricing and insurance support will ultimately determine access to the treatment.

UAE officials insist on security checks

UAE regulators have made it clear that the approval of Foundaio is a controlled medical step, not a mass weight loss solution. The Emirates Drug Establishment said the drug was approved only after a detailed scientific review of its safety, effectiveness and clinical trial performance, adding it was introduced as part of the country’s broader strategy to tackle rising obesity rates.In its official statement, the authority stressed that the move reflects the UAE’s commitment to bringing advanced treatments to patients while maintaining high regulatory standards. Dr Fatima Al Kaabi, Director General of the Authority, said tackling obesity remains a national priority as it is linked to more than 200 diseases, including diabetes, hypertension and cancer. He said the approval marks a shift toward more patient-friendly treatments.Medical experts have also highlighted safety considerations associated with drugs in the GLP-1 receptor agonist class. Clinical data suggests that treatment may cause mild to moderate gastrointestinal side effects such as nausea and vomiting, especially in the early stages or at higher doses.Regulators also emphasize that the pill is not a stand-alone treatment. It is designed for long-term use as part of a structured obesity management plan that includes lifestyle changes such as diet and physical activity. By combining strict prescription controls with ongoing monitoring, UAE authorities aim to ensure that innovation in treatment does not come at the expense of patient safety while expanding access to effective weight management solutions.[Note: The information provided in this article is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any new medication or treatment and before changing your diet or supplement regimen.]